Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Cataract patients tolerate tobramycin and dexamethasone suspension four times daily
Barcelona, Spain-A combination eye-drop formulation of tobramycin and dexamethasone suspension (TobraDex, Alcon) is safe and well tolerated in patients when administered four times daily to control inflammation following cataract surgery.
Related Videos
Related Content
